Mirxes Holding Co. Ltd. Forms Joint Venture with Xeraya to Launch MYRNA Diagnostics in Malaysia

Reuters

Oct 06

Mirxes Holding Co. Ltd. Forms Joint Venture with Xeraya to Launch MYRNA Diagnostics in Malaysia

Mirxes Holding Co. Ltd. has announced the formation of a joint venture with Xeraya Opportunities Fund PCC Limited. The new entity, MYRNA DIAGNOSTICS SDN. BHD., will be owned 40% by Mirxes International Holding Limited, a wholly-owned subsidiary of Mirxes, and 60% by Xeraya. Both parties will contribute a total of approximately US$5 million in cash to the joint venture, in proportion to their respective shareholdings. The joint venture will focus on research, development, commercialization, and regulatory approval of diagnostic solutions, with the aim of improving early disease detection in Malaysia and the region. The partnership is in line with Mirxes' mission to expand access to innovative diagnostic technologies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573209126"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573209126\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573209126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573209126","market":"us","top_or_hot":-1,"title":"Mirxes Holding Co. Ltd. Forms Joint Venture with Xeraya to Launch MYRNA Diagnostics in Malaysia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mirxes Holding Co. Ltd. Forms Joint Venture with Xeraya to Launch MYRNA Diagnostics in Malaysia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mirxes Holding Co. Ltd. has announced the formation of a joint venture with Xeraya Opportunities Fund PCC Limited. The new entity, MYRNA DIAGNOSTICS SDN. BHD., will be owned 40% by Mirxes International Holding Limited, a wholly-owned subsidiary of Mirxes, and 60% by Xeraya. Both parties will contribute a total of approximately US$5 million in cash to the joint venture, in proportion to their respective shareholdings. The joint venture will focus on research, development, commercialization, and regulatory approval of diagnostic solutions, with the aim of improving early disease detection in Malaysia and the region. The partnership is in line with Mirxes' mission to expand access to innovative diagnostic technologies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirxes Holding Co. Ltd. Forms Joint Venture with Xeraya to Launch MYRNA Diagnostics in Malaysia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirxes Holding Co. Ltd. Forms Joint Venture with Xeraya to Launch MYRNA Diagnostics in Malaysia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-06 16:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mirxes Holding Co. Ltd. Forms Joint Venture with Xeraya to Launch MYRNA Diagnostics in Malaysia\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mirxes Holding Co. Ltd. has announced the formation of a joint venture with Xeraya Opportunities Fund PCC Limited. The new entity, MYRNA DIAGNOSTICS SDN. BHD., will be owned 40% by Mirxes International Holding Limited, a wholly-owned subsidiary of Mirxes, and 60% by Xeraya. Both parties will contribute a total of approximately US$5 million in cash to the joint venture, in proportion to their respective shareholdings. The joint venture will focus on research, development, commercialization, and regulatory approval of diagnostic solutions, with the aim of improving early disease detection in Malaysia and the region. The partnership is in line with Mirxes' mission to expand access to innovative diagnostic technologies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL1VFJwZ:1","article_id":"2573209126","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573209126","pubTimestamp":1759739630,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mirxes Holding Co. Ltd. has announced the formation of a joint venture with Xeraya Opportunities Fund PCC Limited. The new entity, MYRNA DIAGNOSTICS SDN. BHD., will be owned 40% by Mirxes International Holding Limited, a wholly-owned subsidiary of Mirxes, and 60% by Xeraya. Both parties will contribute a total of approximately US$5 million in cash to the joint venture, in proportion to their respective shareholdings. The joint venture will focus on research, development, commercialization, and regulatory approval of diagnostic solutions, with the aim of improving early disease detection in Malaysia and the region. The partnership is in line with Mirxes' mission to expand access to innovative diagnostic technologies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02629":"MIRXES-B"},"translate_title":"Mirxes Holding Co.Ltd.与Xeraya成立合资企业，在马来西亚推出MYRNA Diagnostics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02629":0.9},"content_text":"Mirxes Holding Co. Ltd. Forms Joint Venture with Xeraya to Launch MYRNA Diagnostics in Malaysia\n    \n\n        Mirxes Holding Co. Ltd. has announced the formation of a joint venture with Xeraya Opportunities Fund PCC Limited. The new entity, MYRNA DIAGNOSTICS SDN. BHD., will be owned 40% by Mirxes International Holding Limited, a wholly-owned subsidiary of Mirxes, and 60% by Xeraya. Both parties will contribute a total of approximately US$5 million in cash to the joint venture, in proportion to their respective shareholdings. The joint venture will focus on research, development, commercialization, and regulatory approval of diagnostic solutions, with the aim of improving early disease detection in Malaysia and the region. The partnership is in line with Mirxes' mission to expand access to innovative diagnostic technologies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}